Innovative combination clinical trial results revealed at ASCO
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, which begins Friday in Chicago.
The ASCO session brings together more than 32,000 oncology professionals from around the world to share the latest cancer treatment and oncology research results. Among highlighted findings from hundreds of...
Evolutionary selection of pancreatic cancer cells leads to chemoresistance
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...
Novel oncogene hnRNPK identified for B-cell lymphomas
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...
Inducible immune resistance to protect lungs earns prestigious support
Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect against pathogens that cause pneumonia, asthma, and other lung diseases, has earned major funding from the National Heart, Lung, and Blood Institute.
“This research will help protect patients who are most vulnerable to pneumonia, especially patients with cancer,” said Scott Evans, M.D., the principal...
